Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
doi 10.21608/resoncol.2007.372
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Egypts Presidential Specialized Council for Education and Scientific Research

Related search

P2.12-05 SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.12-02 Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Commentary on “Gemcitabine: Single‐Agent and Combination Therapy in Non‐Small Cell Lung Cancer”

Oncologist
Cancer ResearchMedicineOncology
1999English

A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas

American Journal of Hematology
Hematology
2017English

Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma

American Journal of Hematology
Hematology
2017English

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Gemcitabine Plus Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Phase II Study of Three Different Doses

British Journal of Cancer
Cancer ResearchOncology
2000English

Second-Line Pazopanib in Patients With Relapsed and Refractory Small-Cell Lung Cancer: A Multicentre Phase II Study of the Hellenic Oncology Research Group

British Journal of Cancer
Cancer ResearchOncology
2017English

Phase II Trial of Methylglyoxal Bis-Guanylhydrazone (MGBG) in Refractory Small Cell Lung Cancer

Investigational New Drugs
OncologyPharmacology
1990English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy